NDATOPICALAEROSOL, FOAM
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
6/8 — Strong
ZILXI (minocycline) by Journey Medical is 12. Approved for acne vulgaris. First approved in 2020.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZILXI is a topical aerosol foam formulation of minocycline, a tetracycline antibiotic approved for acne vulgaris and rosacea. The mechanism of action remains unknown, though minocycline demonstrates in vitro activity against Propionibacterium acnes with low resistance propensity. The formulation achieves rapid steady-state (Day 6) with minimal systemic accumulation after daily facial application.
$0.403MPart D
Peak4.4 years to LOEEarly peak-phase product with modest Part D penetration (788 claims annually); team likely focused on market share gains and indication expansion.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of AMZEEQ for the treatment of acne is unknown. 12.2 Pharmacodynamics The pharmacodynamics of AMZEEQ for the treatment of acne are unknown. 12.3 Pharmacokinetics In a pharmacokinetic study, male and female subjects 18 years of age or older with acne…
Indications (1)
Worked on ZILXI at Journey Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.